JP2004531457A - Ｔ細胞活性化を調節するための方法および組成物ならびにそれらの使用 - Google Patents

Ｔ細胞活性化を調節するための方法および組成物ならびにそれらの使用 Download PDF

Info

Publication number
JP2004531457A
JP2004531457A JP2002532264A JP2002532264A JP2004531457A JP 2004531457 A JP2004531457 A JP 2004531457A JP 2002532264 A JP2002532264 A JP 2002532264A JP 2002532264 A JP2002532264 A JP 2002532264A JP 2004531457 A JP2004531457 A JP 2004531457A
Authority
JP
Japan
Prior art keywords
ncam
fragment
antagonist
mammal
functional derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002532264A
Other languages
English (en)
Japanese (ja)
Inventor
アンソニー モントゴメリー，
ラリッサ バライアン，
Original Assignee
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2004531457A publication Critical patent/JP2004531457A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2002532264A 2000-10-02 2001-10-02 Ｔ細胞活性化を調節するための方法および組成物ならびにそれらの使用 Pending JP2004531457A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23755500P 2000-10-02 2000-10-02
PCT/US2001/030864 WO2002028440A1 (fr) 2000-10-02 2001-10-02 Procedes et compositions servant a moduler l'activation des lymphocytes t et leurs utilisations

Publications (1)

Publication Number Publication Date
JP2004531457A true JP2004531457A (ja) 2004-10-14

Family

ID=22894231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002532264A Pending JP2004531457A (ja) 2000-10-02 2001-10-02 Ｔ細胞活性化を調節するための方法および組成物ならびにそれらの使用

Country Status (5)

Country Link
EP (1) EP1328298A4 (fr)
JP (1) JP2004531457A (fr)
AU (1) AU2002213001A1 (fr)
CA (1) CA2423436A1 (fr)
WO (1) WO2002028440A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
MX2018006477A (es) 2015-12-02 2018-09-03 Agenus Inc Anticuerpos y metodos de uso de estos.
AU2017359467A1 (en) 2016-11-09 2019-05-02 Agenus Inc. Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof

Also Published As

Publication number Publication date
EP1328298A4 (fr) 2005-05-04
CA2423436A1 (fr) 2002-04-11
AU2002213001A1 (en) 2002-04-15
EP1328298A1 (fr) 2003-07-23
WO2002028440A1 (fr) 2002-04-11
WO2002028440B1 (fr) 2002-05-30

Similar Documents

Publication Publication Date Title
AU2017261541B2 (en) Inhibitors of T-cell activation
Desai-Mehta et al. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production.
Croft et al. Accessory molecule and costimulation requirements for CD4 T cell response
US8460927B2 (en) B7-H1 antibodies and method of use
AU2001275411B2 (en) Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
Guo et al. Identification of a costimulatory molecule rapidly induced by CD40L as CD44H.
US6451305B1 (en) Methods for stimulating T cell responses to tumor cells expressing LFA-3 and a CD28 or CTLA4 ligand
CN1441810A (zh) 可溶性ctla4突变体分子及其应用
EP1973573A2 (fr) Procédés et compositions permettant d'étendre des lymphocytes t régulateurs
TW200539890A (en) Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
Balaian et al. The human neural cell adhesion molecule L1 functions as a costimulatory molecule in T cell activation
JP2004531457A (ja) Ｔ細胞活性化を調節するための方法および組成物ならびにそれらの使用
US20030040477A1 (en) Methods and compositions for modulating t cell activation and uses thereof
EP0795014B1 (fr) SLAM, antigène costimulant de surface de cellules T
WO2007080404A2 (fr) Ligands de leptines
JP2020511992A (ja) 遺伝子組換えｔ細胞調節分子およびその使用方法
Buhlmann et al. 1. WHAT IS COSTIMULATION?
Pastorino Immunotherapy in the Treatment of Human Solid Tumors: Basic and Translational Aspects
WO2015188126A1 (fr) Compositions et méthodes de traitement de tumeurs et de maladies inflammatoires d'origine immunitaire
AU3794299A (en) Methods for modulating T cell unresponsiveness
AU3437902A (en) Methods for modulating T cell unresponsiveness

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040728

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080326